Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota
CRS3123 的安全性、耐受性和药代动力学的多次递增剂量 1 期临床研究，CRS3123 是一种窄谱药物，对正常肠道菌群的破坏最小
期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.1
doi:10.1128/AAC.01395-19
Barbara K Lomeli, Hal Galbraith, Jared Schettler, George A Saviolakis, Wael El-Amin, Blaire Osborn, Jacques Ravel, Keith Hazleton, Catherine A Lozupone, Ronald J Evans, Stacie J Bell, Urs A Ochsner, Thale C Jarvis, Shahida Baqar, Nebojsa Janjic
